Given the pleiotropic and complex nature of the PHD/HIF signaling pathway, it seems desirable that clinically used PHD inhibitors are isoenzyme selective, especially considering their use in chronic diseases such as IBD. Here, PDC is linked to inflammatory bowel disease.